Marshall Wace’s Centessa Pharmaceuticals CNTA Stock Holding History

Marshall Wace’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.68M	Sell	168,177 -47,953	-22%	-$1.23M	0.01%	1159
2025 Q4	$5.41M	Buy	216,130 +102,540	+90%	+$2.6M	﹤0.01%	1116
2025 Q3	$2.75M	Sell	113,590 -229,728	-67%	-$4.08M	﹤0.01%	1466
2025 Q2	$4.51M	Buy	343,318 +207,291	+152%	+$2.63M	0.01%	1191
2025 Q1	$1.96M	Sell	136,027 -3,705	-3%	-$60.6K	﹤0.01%	1473
2024 Q4	$2.34M	Sell	139,732 -41,121	-23%	-$681K	﹤0.01%	1370
2024 Q3	$2.89M	Sell	180,853 -44,095	-20%	-$540K	﹤0.01%	1228
2024 Q2	$2.03M	Sell	224,948 -6,617	-3%	-$62.8K	﹤0.01%	1367
2024 Q1	$2.62M	Buy	+231,565	New	+$2.19M	﹤0.01%	1239

Other funds holding CNTA

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

IVLAV

Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Marshall Wace's CNTA Position: Q1 2026 in Review

Marshall Wace reduced its Centessa Pharmaceuticals (CNTA) stake by 22% in Q1 2026, selling an estimated $1.23M and leaving 168,177 shares worth $6.68M. The position accounts for 0.01% of the portfolio, ranked #1159.

Marshall Wace first reported a position in CNTA in Q1 2024 and has held it in 9 quarters since. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

Marshall Wace held 168,177 shares of Centessa Pharmaceuticals worth $6.68M as of Q1 2026.
Marshall Wace sold 47,953 Centessa Pharmaceuticals shares in Q1 2026, an estimated $1.23M.
Centessa Pharmaceuticals made up 0.01% of Marshall Wace's portfolio in Q1 2026, its #1159 holding.
Marshall Wace first reported a position in Centessa Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.